Horizon Therapeutics (HZNP) PT Raised to $120 at Jefferies on VIE Transaction

Jefferies analyst David Steinberg raised the price target on Horizon Therapeutics (NASDAQ: HZNP) to $120.00 (from $103.00) seeing the $3B VIE transaction as substantially enhancing HZNP’s LT outlook.

The analyst reiterated the Buy rating, stating "Recently launched Uplizna could emerge as HZNP’s next major franchise with potential peak sales exceeding $1B via three separate indications. And we see a real likelihood for upgrades to HZNP’s multiple as VIE’s R&D portfolio should accelerate the growth profile toward the middle part of the decade and offer terminal value."

You May Also Be Interested In

• Procter & Gamble (PG) PT Raised to $168 at Jefferies After Reporting a 7c Beat
• BHP (BHP:LN) (BHP) PT Raised to GBP25.20 at Goldman Sachs
• SMART Global Holdings (SGH) Could Report $9.50 in EPS LT, PT Raised to $65 at Jefferies